Agents reducing cytokine levels

Name
Agents reducing cytokine levels
Accession Number
DBCAT004569
Description

Not Available

Drugs
DrugDrug Description
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
EmapalumabAn interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
EtanerceptA protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.
GolimumabA TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
AfelimomabInvestigated for use/treatment in sepsis and septicemia.
CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA).
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
RilonaceptAn IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.
SecukinumabAn immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.
SiltuximabAn interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
AbataceptA disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
ApremilastA non-steroidal medication used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis.
BimekizumabAn anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.
Drugs & Drug Targets
DrugTargetType
AdalimumabTumor necrosis factortarget
EmapalumabInterferon gammatarget
EtanerceptTumor necrosis factortarget
EtanerceptLymphotoxin-alphatarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
EtanerceptComplement component 1q (C1q)target
GolimumabTumor necrosis factortarget
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
InfliximabTumor necrosis factortarget
AfelimomabTumor necrosis factortarget
CanakinumabInterleukin-1 betatarget
AnakinraInterleukin-1 receptor type 1target
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
RilonaceptInterleukin-1 betatarget
RilonaceptInterleukin-1 alphatarget
RilonaceptInterleukin-1 receptor antagonist proteintarget
SecukinumabInterleukin-17Atarget
SiltuximabInterleukin-6target
SiltuximabCytochrome P450 3A4enzyme
AbataceptT-lymphocyte activation antigen CD80target
AbataceptT-lymphocyte activation antigen CD86target
AbataceptCytotoxic T-lymphocyte protein 4target
ApremilastPhosphodiesterase isozyme 4target
ApremilastCytochrome P450 3A4enzyme
ApremilastCytochrome P450 2A6enzyme
ApremilastCytochrome P450 1A2enzyme
ApremilastP-glycoprotein 1transporter
BimekizumabInterleukin-17Atarget
BimekizumabInterleukin-17Ftarget